Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types.

ABSTRACT:

Purpose

To explore relationships between biological gene expression signatures and pembrolizumab response.

Experimental design

RNA-sequencing data on baseline tumor tissue from 1,188 patients across seven tumor types treated with pembrolizumab monotherapy in nine clinical trials were used. A total of 11 prespecified gene expression signatures [18-gene T-cell-inflamed gene expression profile (TcellinfGEP), angiogenesis, hypoxia, glycolysis, proliferation, MYC, RAS, granulocytic myeloid-derived suppressor cell (gMDSC), monocytic myeloid-derived suppressor cell (mMDSC), stroma/epithelial-to-mesenchymal transition (EMT)/TGFβ, and WNT] were evaluated for their relationship to objective response rate (per RECIST, version 1.1). Logistic regression analysis of response for consensus

SUBMITTER: Cristescu R 

PROVIDER: S-EPMC9762333 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature